Shares of Syros Pharmaceuticals SYRS plunged 86.9% on Wednesday after a late-stage study of its only pipeline candidate, ...

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...

Syros Pharmaceuticals’ blood cancer prospect tamibarotene has failed another study, triggering a default on a loan and wiping ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a ...

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after ...

NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial with its ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

Syros Pharmaceuticals (SYRS) announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...